Evidence map›Paper›PMID 40650115›Full record

ArticleInternational journal of molecular sciences2025

Serum Cereblon (CRBN) Levels Predict Long Term Post- Lenalidomide-Dexamethasone Survival in Multiple Myeloma (MM) Patients and Correlate with Disease Characteristics.

Annita-Ioanna Gkioka, Alexandros Gkiokas, Mavra Papadatou-Gigante, Alexandros Alexandropoulos, Thomai-Marina Tryfou, Aspasia Koudouna, Vasiliki Bartzi, Marie-Christine Kyrtsonis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Annita-Ioanna GkiokaHematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0009-0002-1599-5509
Alexandros GkiokasHematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Mavra Papadatou-GiganteHematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Alexandros AlexandropoulosHematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Thomai-Marina TryfouHematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Aspasia KoudounaHematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0009-0001-3284-3710
Vasiliki BartziHematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Marie-Christine KyrtsonisHematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Funding

European Union 2022-050-0502-52198
6 · The paper itself

Abstract

Serum cereblon (CRBN) has been proposed as a target protein for immunomodulatory drugs (IMiDs). IMiDs are one of the backbone treatment options in multiple myeloma (MM), rendering CRBN an intriguing candidate for use as a biomarker in clinical settings. Ninety-two (92) MM patients, mostly relapsed/refractory and a few at diagnosis, were included in the study, from lenalidomide-dexamethasone (LD) initiation until last follow-up or death. Median CRBN at LD initiation (

Indexed as

Adaptor Proteins, Signal TransducingAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneLenalidomideMultiple MyelomaAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisUbiquitin-Protein LigasesAdaptor Proteins, Signal TransducingBiomarkers, TumorCRBN protein, humanDexamethasoneLenalidomideUbiquitin-Protein LigasesCRBNimmunomodulatory drugslenalidomidemultiple myelomaprognosisresponse biomarkersserum cereblon

Identifiers

PMID40650115
PMCPMC12250050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.